China Drug Deal Will Slash Prices of Three Top-Selling Treatments - Wall Street Journal
Wall Street JournalChina Drug Deal Will Slash Prices of Three Top-Selling TreatmentsWall Street JournalThe monthly price of Iressa would fall 55% to 7,000 yuan ($1,070), Viread would drop 67% to 490 yuan ($75) and Conmana would decline 54% to 5,500 yuan ($840).
Biotech, foreign companies, China - Seeking Alpha
Biotech, foreign companies, ChinaSeeking AlphaShanghai Fosun Pharma (SHA: 600196; HK: 2196) has submitted a non-binding bid to acquire India's Gland Pharma, a contract manufacturer of injectible drugs.
Pharmalot, Pharmalittle: Roche fumes as UK watchdog rejects a drug over cost - STAT
STATPharmalot, Pharmalittle: Roche fumes as UK watchdog rejects a drug over costSTATThe National Health and Family Planning Commission said prices will drop for GlaxoSmithKline's Viread hepatitis B drug and AstraZeneca's lung cancer pill Iressa, along with a lung cancer drug made by China's Betta Pharmaceuticals.
ETF Preview: ETFs, Futures Higher as Worries Over Interest Rate Hike Fade; Existing Home Sales Data Still Ahead - Nasdaq
ETF Preview: ETFs, Futures Higher as Worries Over Interest Rate Hike Fade; Existing Home Sales Data Still AheadNasdaqThe commission said the cost of GlaxoSmithKline's hepatitis drug B drug Viread will fall to 490 yuan ($75) per month from 1,500 yuan, while the price of AstraZeneca's lung cancer pill Iressa will be lowered to 7,000 yuan from 15,000 yuan, Reuters said.
Gilead Has Great Value Now; No Need For It To Make A Big Deal - Seeking Alpha
Smarter AnalystGilead Has Great Value Now; No Need For It To Make A Big DealSeeking AlphaBut, as I show, it has made a number of tuck-in deals ranging from pre-clinical candidates up to a Phase 3-ready one, for 'real money' in aggregate.